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ABSTRACT 
Objective: The present study was designed to evaluate the neuroprotective effect of methanolic extract of Sargassum wightii on haloperidol-
induced catalepsy and tardive dyskinesia in Wistar albino rats. 
Methods: In this study, thirty Wistar albino rats were randomly divided into six groups. Gr-I served as control. Haloperidol (1 mg/kg 
intraperitoneally) was administered to rats of Gr-II to Gr-V for twenty-one consecutive days to induce catalepsy and tardive dyskinesia. Animals of 
Gr-II to Gr-V were orally administered with vehicle, levodopa carbidopa combination (30 mg/kg), Sargassum extract 200 and 400 mg/kg 
respectively. All the drugs and vehicles were given orally one hour before haloperidol injection for twenty one consecutive days. The cataleptic 
scores were recorded using standard bar test. Tardive dyskinesia was assessed in terms of vacuous chewing movement (VCM) and tongue 
protrusion (TP) scores. After behavioural testing, all animals were sacrificed on twenty-second day and various biochemical parameters like MDA, 
SOD and GSH were estimated in brain tissue.  
Results: Chronic administration of haloperidol significantly increased cataleptic scores, VCM and TP scores. (p<0.001) Sargassum wightii extract 
(400 mg/kg) significantly inhibited haloperidol-induced catalepsy, VCM and TP (p<0.001) Haloperidol increased MDA and decreased SOD and GSH 
in brain tissue to a highly significant extent (p<0.001) Sargassum extract at 400 mg/kg also significantly reversed the haloperidol-induced alteration 
in brain oxidative stress markers.  
Conclusion: Sargassum wightii inhibits haloperidol-induced catalepsy and tardive dyskinesia. Thus it may be used as a unique therapeutic adjunct 
for the prevention of neuroleptic-induced extrapyramidal symptoms, however, it has to be explored more.  
Keywords: Sargassum wightii, Catalepsy, Tardive dyskinesia, Oxidative stress, Albino rat 
© 2020 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open-access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) 
DOI: http://dx.doi.org/10.22159/ijpps.2020v12i3.36518. Journal homepage: https://innovareacademics.in/journals/index.php/ijpps 
 
INTRODUCTION 
Neuroleptics used in the treatment of schizophrenia and other 
psychiatric illness are very often associated with extrapyramidal side 
effects like catatonia and tardive dyskinesia [1, 2]. Haloperidol, a typical 
antipsychotic produces extrapyramidal syndrome (EPS) like 
Parkinsonism, due to a blockade of D2 receptors within the striatum and 
reduced dopaminergic transmission [3, 4]. It produces a behavioural 
state of catalepsy and movement disorders like akathisia, dystonia, and 
at last, chronic tardive dyskinesia [5]. Hence haloperidol-induced 
catalepsy is considered as a robust model in rodents to evaluate 
nigrostriatal functions [6]. Evidence from many experimental and clinical 
studies also suggests that neuroleptics induce oxidative stress and cell 
death. Even lipid peroxidation byproducts in blood and cerebrospinal 
fluid are increased in patients with tardive dyskinesia [7, 8]. 
Marine algae or seaweeds have created a significant place in 
pharmaceutical and biomedical fields because they are recognized as 
the rich source of bioactive compounds and secondary metabolites 
like peptides, carotenoids, phenols, terpenoids, phlorotannins, 
flavonoids, fucoidans, phytosterols and glycolipids [9, 10]. Emerging 
researches have scientifically proved the anti-inflammatory, 
anticoagulant, antimicrobial, anticancer, antiviral, antioxidant, 
hypoglycaemic, antiulcer, neuroprotective and hepatoprotective 
effects of some of the seaweeds [11-14]. Several study reports have 
shown that the sulphated polysaccharide of some algae possesses 
free radical scavenging activity which might normalize lipid 
peroxidation [15, 16]. The chemical composition of Sargassum has 
been extensively studied however literature on its bioactivity is 
scarce. One earlier study report has shown that some of the 
constituents of Hypnea musciformis (one of the brown algae) raise 
the level of dopamine and its metabolites that alleviate the 
symptoms in Parkinsonism [17]. Hence it may be hypothesized that 
Sargassum wightii, another species of brown algae containing similar 
phytoconstituents could have a beneficial effect in Parkinsonism 
(PD). Interestingly, over the past decade, there is an amazing rise in 
researches on marine algae. But to our knowledge, scientific data on 
the neuroprotective activity of Sargassum wightii against PD are 
lacking. To bridge this knowledge gap, the current study was 
designed to evaluate the potential benefits of methanolic extract of 
brown seaweeds Sargassum wightii on haloperidol-induced 
catalepsy and tardive dyskinesia in wistar albino rats.  
MATERIALS AND METHODS 
Animal 
Wistar albino rats of either sex (100-150g) were procured from Saha 
Enterprise, Kolkata and maintained in the animal house of Roland 
Institute of Pharmaceutical Sciences, Berhampur. Animals were 
housed and fed with standard pellet diet and water ad libitum and 
maintained under standard conditions temperature (24±1 °C), 
relative humidity (45-55%) and 12:12 light: dark cycle. The animals 
were kept under observation in the laboratory and allowed to 
acclimatize for one week before experimentation. With prior 
permission from the Institutional Animal Ethics Committee (IAEC), 
(Regd. No: 926/PO/Re/S/06/CPCSEA), Approval No-86/IAEC/ 
RIPS/07.04.2017, handling and care of animals during 
experimentation were followed as per CPCSEA guidelines. The 
experiments were conducted between 10.00 to 16.00h.  
Plant material 
The plant material was a gift sample from Microbiotech limited, 
Gujrat India. The dried samples were coarsely ground to a fine 
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powder using electrical blender before extraction. To prepare the 
methanolic extract of Sargassum, 40 gm of powder sample was 
extracted with 400 ml of methanol by using soxhlet’s apparatus for 
72h. The extract obtained was dried in an evaporator and stored at 4 
°C for further use [18]. Different concentration of drug solution was 
freshly prepared on the day of the experiment using 1% CMC 
suspension. 
Chemicals 
Haloperidol was purchased from Sigma, Aldrich USA; Levodopa and 
carbidopa combination: Glaxo Smithkline Pharmaceuticals, India; 
Carboxymethyl Cellulose(CMC), Thiobarbituric Acid (TBA), 
Trichloroacetic Acid (TCA), Dithiobis Nitro benzoic Acid (DTNB), 
phosphate buffer and all other chemicals used were of analytical grade 
and obtained from Himedia Laboratories Pvt Ltd, Mumbai, India. 
Phytochemical screening of plant extract 
The methanolic extract of S wightii was subjected to phytochemical 
screening test by the method described earlier [19] and it revealed 
the presence of polyphenols, terpenoids, tannins, flavonoids, 
polysaccharides like glycolipids, etc. 
Acute toxicity test 
Acute toxicity study was done as per OECD Guidelines 423 [Limit test]. 
The extract at doses 5, 50, 1000, 2000 mg/kg were given orally in 
stepwise form. The rats were observed for 24 h. There was no mortality 
or behavioral changes observed during the study period [20]. 
Experimental design 
Haloperidol (1 mg/kg) was injected intraperitoneally for 21 d to 
induce catalepsy and tardive dyskinesia [21]. The test drugs and 
vehicles were given orally for 21 d, one hour before haloperidol 
injection. Thirty albino rats were randomly divided into five groups 
(n=6 in each group) to receive treatments as follows. 
Group-I (control) received vehicle (1% CMC 0.5 ml/Rat).  
Group-II (disease control) received 1% CMC.+Haloperidol 
Group-III (standard) was treated with L-Dopa, carbidopa 
combination (30 mg/kg)+Haloperidol [21] 
Group IV and V animals (test groups) received the methanolic 
extract of Sargassum wightii at the doses of 200 and 400 mg/kg 
respectively and were co-administered with Haloperidol (ip) 
Then all the rats were subjected to behavioral and biochemical 
assessments. On the 22nd day, following behavioral assessment, the 
animals were sacrificed by cervical dislocation. The brains were 
removed, the forebrain was dissected and a 10% (w/v) of brain 
tissue homogenate was prepared in 0.1M phosphate buffer (PH-7.4) 
Haloperidol-induced catalepsy 
In this model, haloperidol 1mg/kg/ip was administered daily for 21 
successive days to elicit a moderate to the high degree of catalepsy 
and it was scored as a measure of reduced ability to move and 
failure to maintain the correct posture using standard bar test. [22] 
Catalepsy was assessed in terms of time for which the animal 
maintained an imposed posture with both the front limb raised and 
resting on the 9 cm height wooden bar and scored accordingly. The 
endpoint of the catalepsy was considered when both the front paws 
were removed from the bar. If the animal maintained this position 
for 20 s or more it was said to cataleptic, given one point and every 
further 20 s was given more extra points (numbers). A cut-off time 
300 sec was applied for scoring. The severity of catatonia was 
observed on the 7th, 14th and 21st days of haloperidol and test drug 
administration [23]. 
Haloperidol-induced tardive dyskinesia 
For this experiment, 24 h after the last test dose (on the 22nd day), 
the animals were placed individually in small cages (30 x 20 x 30 
cm). Then each animal was allowed to acclimatize to the observation 
cage for 10 min. The vacuous chewing movement (VCM) and tongue 
protrusion (TP) were observed for 5 min and scored. VCM was 
referred to as single mouth openings in the vertical plane not 
directed toward physical material. Individual tongue protrusions 
during oral dyskinesia were preceded by visible retraction of the 
tongue. If tongue protrusions or vacuous chewing movements 
occurred during a period of grooming, they were not taken into 
account [24]. 
Biochemical estimation 
Lipid peroxidation assay (TBARS)  
Lipid peroxidation was assayed by measuring the level of 
malondialdehyde (MDA) in the brain. Malondialdehyde was 
determined by measuring thiobarbituric reactive species using the 
method of Okhawa et al. 1996. In which the thiobarbituric acid 
reactive substances react with thiobarbituric acid to produce a red 
colour complex having peak absorbance at 532 nm [25]. 
Reduced glutathione assay 
Reduced glutathione (GSH) was determined by the method of Sedlak 
J et al. 1968. The procedure is based on the reduction of Ellman´s 
reagent by–SH groups of GSH to form 2-nitro-s-mercaptobenzoic 
acid, the nitromercaptobenzoic acid anion has an intense yellow 
color which can be determined spectrophotometrically. (Shimadzu 
UV-1800) The amount of glutathione in tissue is expressed as μg/mg 
tissue [26]. 
Superoxide dismutase assay 
The enzyme activity of superoxide dismutase in brain tissue was 
assessed using the method of Marklund and was expressed in terms 
of units of SOD activity/mg of tissue [27]. 
Statistical analysis 
The observations were shown as mean±SEM. The data were 
analyzed using One-Way ANOVA followed by Tukey’s post hoc test. 
Data analyses were performed using statistical software, Graph pad 
Prism 7. A probability value of less than 0.05 was considered as a 
minimum level of significance. 
RESULTS 
Phytochemical screening 
The phytochemical screening of Sargassum extract revealed the 
presence of flavonoids, phenolic compounds, sterols, tannins, 
saponins, and glycolipids. 
Acute toxicity test 
On acute toxicity test, up to 2000 mg/kg body weight, no behavioral 
changes or mortality were observed within the study period. 
Effect of methanolic extract of S wightii (SWE) on haloperidol-
induced catalepsy 
In this experiment, Haloperidol induced cataleptic score was 
significantly increased on 7th, 14th and 21st days of treatment in 
comparison to that of the control group (p<0.001). Standard drug L-
dopa-carbidopa (30 mg/kg) decreased cataleptic score significantly 
on the 7th, 14th and 21st days of treatment as compared to that of 
haloperidol treated group on respective days. (p<0.001) However, 
pre-treatment with the test drug (SWE) at 200 mg/kg and 400 
mg/kg reduced the cataleptic score to a highly significant extent only 
on the 14th and 21st days of observation when compared with the 
haloperidol control group on respective days. (p<0.001) table 1 
Effect of administration S wightii on haloperidol-induced 
tardive dyskinesia in rats  
On chronic administration, haloperidol increased the VCM and TP on 
the14th and 22nd days of treatment to a highly significant extent in 
comparison to that of the normal control group (p<0.001). With L 
dopa-carbidopa 30 mg/kg, the reference standard drug treatment, 
there was a highly significant decrease in the Haloperidol induced 
VCM and TP throughout the study period. (p<0.001) Sargassum 
wightii 200 mg/kg reduced the haloperidol-induced VCM and TP 
significantly only on the 22nd day of treatment as compared to that of 
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Haloperidol control. (p<0.01) However, pre-treatment of S wightii 
400 mg/kg reduced VCM and TP to a highly significant extent both 
on the 14th and 22nd days of treatment when compared with the 
haloperidol treated control group (table 2). 
 
 
Fig. 1: Effect of S wightii on brain MDA levels. One way ANOVA followed by Tukey’s multiple comparison tests was applied for analysis. #: 
p<0.001 when compared to the vehicle control group. **p<0.01; ***p<0.001; test group vs haloperidol control group 
 
 
Fig. 2: Effect of methanolic extract of Sargassum wightii on GSH levels in the brain. One way ANOVA followed by Tukey’s multiple 
comparison tests was applied for analysis. #: p<0.001 when compared to the vehicle control group. ***: p<0.001; test group vs haloperidol 
control group 
 
Table 1: Effect of methanolic extract of Sargassum wightii on haloperidol-induced catalepsy 
Group Treatments Mean cataleptic score 
7th day  14th day 21st day 
I Vehicle 4.85±0.31 3.95±0.18 4.18±0.37 
II Haloperidol(1 mg/kg, ip) 117.4±2.38# 130.6±2.22# 126.7±5.57# 
III L Dopa-carbidopa (30 mg/kg)+Haloperidol 50.12±2.13*** 36.03±1.21*** 29.17±1.03*** 
IV S. wightii (200 mg/kg)+Haloperidol 114.4±4.11 95.60±3.03*** 73.90±3.03*** 
V S. wightii (400 mg/kg)+Haloperidol 104.8±4.88 81.92±2.44*** 55.98±2.65*** 
Values are expressed as mean±SEM, n=6. One way-ANOVA followed by Tukey’s multiple comparison test was applied for analysis. #P<0.001 when 
compared with the vehicle group. ***: P<0.001 test group vs haloperidol control group. 
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Table 2: Effect of methanolic extract of Sargassum wightii on haloperidol-induced tardive dyskinesia 
Group Treatments  VCM/5 min TP Frequency/5 min 
14th day 22nd day 14th day 22nd day 
I. Vehicle 0.5±0.22 0.833±0.31 2.83±0.6 2.5±0.67 
II. Haloperidol(1 mg/kg ip) 14.33±1.50# 30.17±1.7# 26.83±3.02# 34.83±3.26# 
III. L-Dopa-carbidopa (30 mg/kg)+Haloperidol 4.67±0.61*** 8.67±0.88*** 8.5±1.8*** 7.33±1.26*** 
IV S. wightii (200 mg/kg)+Haloperidol 12.33±1.52 23.33±1.28** 18.83±1.96 24.17±2.41* 
V S. wightii (400 mg/kg)+Haloperidol 7.33±0.88** 17.83±0.83*** 15.67±2.14** 18.33±3.18*** 
Values are expressed as mean±SEM, n=6. One way-ANOVA followed by Tukey’s multiple comparison tests was applied for analysis. #P<0.001 when 
compared with the vehicle group. *: p<0.05 **: P<0.01; ***: P<0.001 test group vs haloperidol control group. 
 
Effect of methanolic extract of S wightii (SWE) on haloperidol-
induced changes in various biochemical parameters 
On chronic haloperidol administration, the TBAR level in the brain was 
increased to a highly significant extent with a concomitant decrease in 
GSH and SOD in comparison to that of the control group (p<0.001). 
When compared with the haloperidol treated control group, L dopa-
carbidopa (30 mg/kg-Gr III), as well as S wightii (400 mg/kg-GR V), 
significantly reduced the haloperidol-induced increase in TBAR with a 
concurrent significant rise in GSH and SOD. fig. 1, 2, 3. 
 
 
Fig. 3: Effect of S. wightii on SOD level in the brain. One way ANOVA followed by Tukey’s multiple comparison tests was applied for 
analysis. #: p<0.001 when compared to the vehicle control group. ** p<0.01; ***: p<0.001; test group vs haloperidol control group 
 
DISCUSSION 
Haloperidol induced catalepsy (HIC) is a widely accepted animal 
model to test the effect of drugs modulating the extrapyramidal side 
effects of antipsychotic drugs [22, 28]. Haloperidol, a non-selective 
dopamine antagonist provides an experimental model in rodents 
simulating PD in human beings. It blocks dopamine receptors and 
interferes with dopamine transmission in the striatum. Thus the 
drugs which increase the dopamine transmission in the nigrostriatal 
pathway and inhibit HIC. Moreover, evidence in support of the “free 
radical hypothesis” proposes that the free radical byproducts of 
dopamine metabolism impart neurotoxic effects at basal ganglia and 
substantia nigra which explains one of the mechanisms involved in 
the process of neurodegeneration in neuroleptic-induced tardive 
dyskinesia and PD [29, 30].  
In the present study, chronic administration of haloperidol (1 mg/kg 
ip) induced significant catalepsy. Treatment with methanolic extract 
of S. wightii (SWE) at both 200 mg/kg and 400 mg/kg doses, showed 
a protective effect against haloperidol-induced catalepsy 
significantly on 14thand 21stdays of the study period (table 1). It 
indicates that this seaweed extract can protect dopaminergic 
neurotransmission in the nigrostriatal pathway. Similar 
observations were made by B. S. Nishcal et al., 2014 who have 
reported the protective effect of Tribulus terrestris plant against HIC 
and this effect was attributed to its dopamine facilitatory activity 
[31]. The anti-cataleptic activity of other plant extracts (Ocimum 
sanctum, Ellagic acid) also supports this hypothesis [32, 33] we also 
observed that the administration of S wightii (SWE) for 21 
successive days reversed the haloperidol-induced tardive dyskinesia 
(TD) or orofacial dyskinesia. Even this effect of S wightii 400 mg/kg 
was comparable to that of L dopa and carbidopa (table 2). Our 
observations corroborate with that of Dhansekharan et al., 2010 
who have shown the amelioration of haloperidol-induced tardive 
dyskinesia by Mucuna puriens [24]. 
Oxidative stress generated as a result of mitochondrial dysfunction 
plays an important role in the pathogenesis of PD. Lipid 
peroxidation, a sensitive marker of oxidative stress impairs 
membrane function, distorts structural integrity and inactivates 
several membrane-bound enzymes present in all biological 
membranes. Superoxide dismutase (SOD) helps in neutralizing the 
free radical-induced toxic effects. Even depletion of glutathione is a 
positive correlate of the extent of neuronal loss. Evidences show that 
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a rise in MDA, decrease SOD and depletion of GSH in the brain result 
in neuronal loss (substantia nigra) and are important factors of the 
etiology of PD [34].  
In the present study, haloperidol-treated animals exhibited an 
increase in the level of lipid peroxidation and decreased level of 
protective antioxidants such as GSH and SOD, suggesting a possible 
free radical generation. Previous studies have also reported that 
haloperidol-induced catalepsy is associated with oxidative stress 
[23, 24, 30] Treatment with methanolic extract of S wightii reversed 
the haloperidol-induced changes in oxidative stress markers like 
MDA, GSH and SOD significantly (fig. 1,2,3). Our observations are in 
accordance with that of Yuvraj et al., 2014 who have shown the 
antioxidant activity of S wightti in an in vitro model [17]. Since the 
neuroleptic-induced extrapyramidal syndrome is correlated with an 
increase in free radical production it can be assumed that the 
antioxidant property of SWE could be another protective factor in 
the prevention of neurodegeneration in PD. Such correlation was 
also made by Perwez et al. who have shown the neuroprotective 
effect of Mentha arvensis against haloperidol-induced catalepsy in 
mice [23]. 
Studies on neuroprotective and antioxidant activities of Sargassum 
species have substantiated the role of various phytoconstituents. 
Presence of phenols, phytosterols, flavonoids, carotenoids, 
fucoxanthin, polysaccharides (fucoidan) and tannins in Sargassum 
(seaweeds) contribute to their promising antioxidant, anti-
inflammatory and neuroprotective properties [35-37]. The plant of 
our research interest, Sargassum wightii contains the same 
phytoconstituents. Hence its neuroprotective effect observed in our 
research could also be attributed to its promising antioxidant 
activity. Further study is required in other experimental and clinical 
models of PD to elucidate the exact mechanism of neuroprotective 
activity of S wightii. In the present investigation, the isolation of 
individual phytochemicals and their effects on biogenic amines in 
the brain could not be done which directs future research.  
CONCLUSION 
Our study suggests that the Sargassum wightii inhibited the 
extrapyramidal features and reversed the altered oxidative stress 
parameters induced by haloperidol. Hence it can be a novel 
approach for the prevention of extrapyramidal side effects of 
neuroleptics. The naturally occurring phytochemicals present in 
Sargasssum wighitii possessing neuroprotective and antioxidant 
properties with little toxicities pose a new insight for further 
research in this field. 
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